ICER Reschedules Cystic Fibrosis Public Meeting for August 27, 2020

— Registration is now open —

BOSTON, July 8, 2020 – The Institute for Clinical and Economic Review (ICER) announced today that the public meeting to discuss the comparative clinical effectiveness and value of treatments for cystic fibrosis is rescheduled to August 27, 2020, and will be held virtually. This public meeting was previously postponed due to the COVID-19 pandemicThe Evidence Report will be subject to deliberation during this public meeting of the California Technology Assessment Forum (CTAF), one of ICER’s three independent evidence appraisal committees.

Released in April 2020, the Evidence Report analyzed the comparative clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (Trikafta®, Vertex Pharmaceuticals) for the treatment of cystic fibrosis. ICER also examined new data that became available since its May 2018 review of three related CF treatments: ivacaftor (Kalydeco®, Vertex), lumacaftor/ivacaftor (Orkambi®, Vertex), and tezacaftor/ivacaftor (Symdeko®, Vertex). All four therapies are CFTR modulators.

The Evidence Report reflects changes made based on comments received from patient groups, clinicians, drug manufacturers, and other stakeholders. Detailed responses to public comments can be found here.

Register for the Virtual Public Meeting
The independent council will vote on key questions raised in the report. Registration for the virtual public meeting is now open.

ICER still plans to post a final evidence report & meeting summary, final policy recommendations, and a report-at-a-glance on September 23, 2020.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.

ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.